These ideas have led to considerable efforts focused on developing efficient and selective epigenetic inhibitors, including one EZH2 inhibitor, tazemetostat (EPZ-6438), which is FDA-approved for follicular lymphoma and epithelioid sarcoma [42]. This evidence concerns the gene EZH2 and follicular lymphoma.